Fecal Microbiota Transplantation & Diabetes Mellitus

Gut microbiota and type 2 diabetes mellitus.


Role of Gut Microbiota in Type 2 Diabetes Mellitus and Its Complications: Novel Insights and Potential Intervention Strategies.


Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?


Promising Treatment for Type 2 Diabetes: Fecal Microbiota Transplantation Reverses Insulin Resistance and Impaired Islets.


Fecal microbiota transplantation alters the susceptibility of obese rats to type 2 diabetes mellitus.


Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes.


Microbiome and diabetes: Where are we now?


Research progress in the relationship between type 2 diabetes mellitus and intestinal flora.


Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice.


Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes.


Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?


Implications of the Intestinal Microbiota in Diagnosing the Progression of Diabetes and the Presence of Cardiovascular Complications.


Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.


Targeting gut microbiota as a possible therapy for diabetes.




Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes.


Perturbations of gut microbiota in gestational diabetes mellitus patients induce hyperglycemia in germ-free mice.

Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.


[Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].


From role of gut microbiota to microbial-based therapies in type 2-diabetes.


Gut commensal Parabacteroides goldsteinii plays a predominant role in the anti-obesity effects of polysaccharides isolated from Hirsutella sinensis.


Distinct fecal and oral microbiota composition in human type 1 diabetes, an observational study.


Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis.


Insights into the role of the microbiome in obesity and type 2 diabetes.


Bone Marrow-Derived Cells Restore Functional Integrity of the Gut Epithelial and Vascular Barriers in a Model of Diabetes and ACE2 Deficiency.


Gut microbiota composition alterations are associated with the onset of diabetes in kidney transplant recipients.


Gut Microbiota as a Therapeutic Target for Metabolic Disorders.


Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time.


Impact of HIV and Type 2 diabetes on Gut Microbiota Diversity, Tryptophan Catabolism and Endothelial Dysfunction.


Pancreatic Diseases and Microbiota: A Literature Review and Future Perspectives.


Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective.


Role of Intestinal Microbiome in Lipid and Glucose Metabolism in Diabetes Mellitus.


Role of Gut Microbiota on Onset and Progression of Microvascular Complications of Type 2 Diabetes (T2DM).


Gut microbial degradation of organophosphate insecticides-induces glucose intolerance via gluconeogenesis.


Early-life exposure to gut microbiota from disease-protected mice does not impact disease outcome in type 1 diabetes susceptible NOD mice.


Prolonged antibiotic treatment induces a diabetogenic intestinal microbiome that accelerates diabetes in NOD mice.


[The microbial flora in the digestive tract and diabetes].